Express Scripts said this week that it expects US drug spending to rise about 2% over the next 3 years, lower than projected inflation rates. However, a lack of competition will affect 2 of the costliest categories of pharmaceuticals—inflammatory conditions and diabetes—between 2019 and 2021.
Express Scripts said this week it expects US drug spending to rise about 2% over the next 3 years, lower than projected inflation rates.
However, a lack of competition will affect 2 of the costliest categories of pharmaceuticals—inflammatory conditions and diabetes—between 2019 and 2021, Express Scripts said in its annual drug trend report. Biosimilar savings for rheumatoid arthritis and other inflammatory conditions will not begin to show up in earnest until 2020, the company said, so cost increases for brand-name drugs will continue.
In diabetes, competition for sitagliptin (Januvia) generics will not become available until 2023. The aging population as well as the increase in obesity will continue to drive usage of diabetes medications, the report said.
In another category, multiple sclerosis, pharmaceutical spending declined in 2018 but may reverse in the next 3 years, Express Scripts said, due to a market shift as patients switched from an older medication, dimethyl fumarate, to a biologic: ocerelizumab.
The pharmacy benefits manager (PBM), which recently merged with Cigna, also touted the fact that its commercial clients saw a spending increase of just 0.4%, which the company said was a 25-year low. Half of the plans decreased drug spending in 2018, up from 44% the year before.
Spending on specialty drugs rose 9.4%, mostly due to better access to therapies, the company said. Spending on traditional, non-specialty medications fell 5.8%.
The company cited its value-based care program for helping to achieve lower increases, and said plans enrolled in the program performed better than traditional plans. As one example, it said plans using its diabetes care management program spent 4.3% less in 2018 even as utilization went up; plans not enrolled spent 7.5% more.
Despite list price inflation of 7.3% for the most commonly used traditional brand medications in 2018, drug costs for traditional drugs fell by 6.5% for employer-sponsored plans, 5.5% for Medicare plans, and 5.6% for exchange plans.
Inflammatory drugs comprised the costliest therapy class for the third year in a row, costing employers $174.45 per member per year, up 14%. Diabetes came in second at $114.85 per member per year, an increase of 4.1%. Spending on insulin, which accounts for 15.3% of diabetes prescriptions, increased just 0.3% in 2018, with a 1.5% decline in unit costs and a 1.8% rise in utilization. In 2018, patients paid 16.9% of total insulin costs, an average of $43.19 per prescription, up $3.33 from 2017.
The Express Scripts report was released the day after President Trump’s State of the Union address, in which he promised once again to lower drug prices, and the same week that HHS Secretary Alex Azar made the rounds at various health policy conferences vowing to bring an end to rebates in an effort to create a more transparent pricing system. Last week, HHS released a rule that, if enacted, would block rebates and discounts given to PBMs, Part D plans, and Medicaid managed care organizations
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.